demonstrated by autoradiographic and biochemical methods, and the cells have also been shown to respond to calcitonin with a dose-dependent increase in cyclic AMP. The receptors in rat osteoclasts are specific and of high affinity (dissociation constant, Kd, 1 to 6 X 10(-10) M), and are present in greater numbers than in any cell previously studied (greater than 10(6) per cell). Chemical cross-linking of 125I-labeled salmon calcitonin to osteoclasts using disuccinimidyl suberate resulted in identification of a receptor component with a relative molecular weight of 80,000-90,000. By counting grains in autoradiographic experiments, we found that greater than 80% of specifically bound radioactivity was associated with multinucleate osteoclasts and the remainder was associated with mononuclear cells that are not osteoblasts, but that may be osteoclast precursors. by autoradiographic and biochemical methods, and the cells have also been shown to respond to calcitonin with a dose-dependent increase in cyclic AMP. The receptors in rat osteoclasts are specific and of high affinity (dissociation constant, Kd, 1 to 6 X 10-10 M), and are present in greater numbers than in any cell previously studied (>10' per cell). Chemical cross-linking of "SIlabeled salmon calcitonin to osteoclasts using disuccinimidyl suberate resulted in identification of a receptor component with a relative molecular weight of 80,000-90,000. By counting grains in autoradiographic experiments, we found that >80% of specifically bound radioactivity was associated with multinucleate osteoclasts and the remainder was associated with mononuclear cells that are not osteoblasts, but that may be osteoclast precursors.
Introduction
Calcitonin inhibits bone resorption (1) by acting directly on osteoclasts to reduce their number and activity (2) , and in vivo autoradiographic studies have localized calcitonin binding to osteoclasts in bone (3) . There is no evidence for a direct action of calcitonin upon osteoblasts or osteocytes, although osteocyte shrinkage has been observed to take place after calcitonin administration (4) . Thus, the osteoclast is the principal physiological target for calcitonin, and this is the basis of its therapeutic use in, for example, Paget's disease of bone. It has previously been impossible to carry out direct in vitro studies of the calcitonin receptor in osteoclasts because of the difficulty of preparing a pure population of osteoclasts in sufficient numbers. For that reason most of the available information on calcitonin-receptor interactions was derived from studying the calcitonin receptor in certain cancer cell lines. We report an abundance of calcitonin receptors in osteoclasts isolated from newborn rat bone, as shown by autoradiographic and biochemical methods (5) (6) (7) . The large number of receptors in these osteoclasts has made it possible, for the first time, to characterize the osteoclast calcitonin receptor on small numbers of cells using methods we have previously applied to the identification and characterization of calcitonin receptors in certain cancer cell lines (8) (9) (10) (11) (12) Osteoclast isolation and culture. Osteoclasts were prepared from 1-or 2-d-old Sprague Dawley rats as previously described (5-7). Femora, tibiae, and humeri were cleaned ofsoft tissue, cut across at the diaphysis, split longitudinally, and curetted into Medium 199 with 5% FCS (199/ FCS) (1 ml per six bones). Cell suspensions were pipetted into the wells ofsix-well Teflon-Perspex molds clamped to glass microscopy slides (for autoradiographic experiments) or onto 22-mm-diam glass coverslips in six-well Costar tissue culture plates (for binding studies or hormone responses). After incubation at 370C for 20 min, surfaces were washed vigorously with medium to remove less adhesive cells, and incubated with fresh 199/FCS for 2 h before experiments were begun.
Autoradiography. Osteoclasts were grown on glass slides within wells made from Teflon-Perspex molds. 24 h previously, these wells had been lightly seeded with either calvarial osteoblasts (13) or UMR 106-01 osteogenic sarcoma cells (14) , which are phenotypically osteoblast and have no calcitonin receptors or responses. sCT was labeled with 1251 as previously described to preserve biological activity (8, 9) , using 1 ug chloramine T for 10 s as oxidant, and purification with QUSO G32, elution and storage at -20'C in 20% acetone-1% acetic acid. Specific activities ranged from 150 to 200 ,Ci/hlg. Cells (13) , and no radioactivity was associated with these cells. The autoradiographs shown in Fig. 1 A, ments without added osteoblasts, we determined that >80% of the total specifically cell-bound radioactivity in these experiments was associated with multinucleate osteoclasts; the remainder was associated with the mononuclear (nonosteoblast) cells (Table I) . Note also that the grains per unit area in association with the mononuclear cells were less than with osteoclasts (P < 0.05, paired t test), and were more variable, consistent with heterogeneity of numbers of binding sites per cell within the mononuclear population. Binding of'251-salmon calcitonin to isolated rat osteoclasts. Fig. 2 illustrates specific binding of '25I-sCT to osteoclasts, with competition by unlabeled sCT. The relative efficacies of hCT and Gly8-hCT reflect their relative abilities to compete for binding to the calcitonin receptor in human cancer cells (8) (9) (10) 18) and to lower serum calcium in the rat (17) . Several unrelated peptides (insulin, parathyroid hormone, glucagon, and ACTH) to concentrations of 1 ,ug/ml had no effect on 1251-sCT binding to osteoclasts (data not shown). Based on Scatchard analysis of separate competition binding experiments similar to that of Fig.  2 the mean calcitonin receptor numbers were 7.3±1.7 (n = 3, mean±SEM) million per cell, with dissociation constants (Kd) of 5.6±0.8 X 10-' M. Similar values were obtained by Scatchard analysis of saturation binding data (Fig. 3) , in which receptor numbers were 4.5±0.1 (n = 3) million per cell, with Kd of 1.6±0.1 X 10-1°M. The r value for the Scatchard line in Fig. 3 After 125I-sCT had been bound to osteoclasts on coverslips at 220C, they were washed and incubations continued at 220C for up to 5 h in medium with or without excess unlabeled sCT at the same temperature. No significant loss of cell-bound radioactivity occurred under these conditions (Fig. 4 ), but at 370C there was progressive dissociation resulting in removal of 55% of the bound radioactivity by 5 h (data not shown).
Cross-linking of '25I-salmon calcitonin to osteoclasts. SDS-PAGE analysis of solubilized cells following cross-linking of '25I-sCT revealed a broad band of radioactivity of approximate molecular weight 80,000-90,000 (Fig. 5) .
Cyclic AMP response to salmon calcitonin in osteoclasts. A sensitive, dose-dependent increase in cyclic AMP was obtained in response to sCT treatment of isolated osteoclasts (Fig. 6 ).
Discussion
The development of methods to isolate viable osteoclasts provides the means, for the first time, to investigate calcitonin interaction with its major target cell in bone. From the present data it is clear that osteoclasts isolated from newborn rat long bone contain large numbers of calcitonin receptors, and that apart from osteoclasts, the only other cells in these isolates which are capable of detectable binding of calcitonin are mononuclear cells, which on morphological and histochemical grounds are not osteoblasts. This latter group of cells could consist of mononuclear precursors of osteoclasts, some ofwhich are in the process of expressing calcitonin receptors as part of their development. As such, they are of considerable interest and will warrant very careful study with a number of techniques, to obtain further information about pathways of osteoclast development. In their in vivo autoradiographic study of 251I-labeled salmon calcitonin localization in rats, Warshawsky et al. (3) drew attention to specific radioactivity in association with mononuclear cells of uncertain identity, which, on the basis oftheir electron microscopic studies, they felt to be "cell fragments" of osteoclasts. Such an explanation could not apply to those in the present experiments. It is generally considered that osteoclasts develop from mononuclear precursors of the monocyte/macrophage series (24) (25) (26) (27) , although it has also been suggested that they might derive from a different type of marrow stem cell (28) . In either case the origin 0t3- of osteoclasts is believed to be through a lineage quite distinct from that of osteoblasts. The development of a detectable calcitonin receptor might be a valuable marker in osteoclast ontogeny, and for that reason further efforts are being made to characterize the osteoclast calcitonin receptor. Previous biochemical studies ofthe calcitonin receptor have been confined to nonbone cells. Thus, calcitonin receptors have been identified in kidney (23, 29, 30 ), brain (20, 31) , testis (32), pig lung (22), fish gill (21), certain lymphoid cell lines (33) , and human cancer cell lines (8-12, 18, 34-37) . The specificity of calcitonin binding to the cells in the present experiments was demonstrated by the lack of competition for binding by nonrelated peptides, and by the relative efficacies ofhuman calcitonin and Gly8-human calcitonin, which are similar to those obtained in other well-characterized calcitonin responsive systems (9, 10, 17, 18) . Furthermore, we have identified in breast cancer and lung cancer cells an 85,000 molecular weight receptor component, using photoaffinity labeling (11, 36) . Until now, the most abundant source of calcitonin receptors has been the human breast and lung cancer cell lines, with calculated receptor numbers of 5,000-30,000 per cell (9, 10, 37) . Although only small numbers of osteoclasts can be obtained with the present approach, substantial specific binding can be measured readily, with very low nonspecific binding. From our data it is clear that the rat osteoclast is extremely rich in calcitonin receptors that are specific and saturable. It must be stressed that the calculations of receptor numbers and binding constants provide only approximate values, since the calcitonin binding is poorly reversible. This has been a constant feature ofsalmon calcitonin binding in all systems in which it has been studied (12, [18] [19] [20] [21] [22] [23] , and for that reason we have emphasized the limitations ofcalculations of binding constants and receptor numbers (9, 12, 18 It is thought that in mammalian cells the initial action of calcitonin upon osteoclasts requires activation of adenylate cyclase. This is based on activation of adenylate cyclase by calcitonin in bone membrane preparations (23) , increase of cAMP in "osteoclast-rich" cultures from rodent calvaria (39) , and the lack of evidence for an effect of calcitonin on cyclic AMP production in osteoblast-like cells (13, 39) . In the present experiments a sensitive dose-dependent increase in cAMP was found with calcitonin treatment of the cultures. In other work, using immunocytochemical methods, we have shown that calcitonin treatment of rat osteoclasts is associated with an increase in cy- The present work provides a basis for studying its significance, besides offering a means of studying directly in osteoclasts some particular features of calcitonin action which might be related to its therapeutic use. These include the phenomena of calcitonin-induced receptor loss (43, 44) , "escape" (45) , persistent activation of adenylate cyclase (12, 46), and homologous desensitization (12, 43).
